BPMC (Blueprint Medicines Corp.) Aset Bersih Perusahaan

The confirmed price history on the Blueprint Medicines (BPMC) chart highlights the business's protection via patents and strict FDA control, which limits the entry of new players. The company's profitability relies on the sale of specialized mastocytosis treatments, while the 0.34 metric confirms the stability of cash flows. However, expansion requires competing with global behemoths for leadership in the field of precision medicine.

Blueprint Medicines Corp. (BPMC) - Nilai Buku Perusahaan saka 04.07.2022 nganti 02.08.2025

Rincian metrik komprehensif lan analitis Blueprint Medicines Corp (BPMC)

- rega lan prakiraan konsensus rega:

Kutipan saham Blueprint Medicines|BPMC - Prakiraan konsensus analis

- data kapitalisasi pasar:

Biji pasar Blueprint Medicines Corp.|BPMC - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Aset Bersih saben Saham Blueprint Medicines|BPMC - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Nilai Buku blueprintmedicines.com|BPMC - Total Aset Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas Blueprint Medicines|BPMC - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang modal Blueprint Medicines|BPMC - Utang perusahaan|Rasio utang marang kapitalisasi buku Blueprint Medicines Corp.|BPMC - Utang jangka dawa perusahaan|Utang jangka cendhak Blueprint Medicines

Analisis wiwitan perusahaan:Blueprint Medicines Corporation - BPMC

Barang unggulan Blueprint Medicines Corp.

An analysis of Blueprint Medicines (BPMC) resilience to market shocks is supported by expanding margins within its oncology portfolio and the elimination of liquidity shortages. The trend in total book capitalization, reflecting the daily market equilibrium of net assets, allows investors to verify the business's intrinsic value and exclude hidden technological risks, confirming the fundamental reliability of the company's current growth trajectory.

Pesaing wigati